Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab Phase 1 Study in Healthy Chinese Participants
NCT05533411Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of donanemab in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment Emergent Adverse Events at Day 85 and Serious Adverse Events at Day 85. Started Sep 2022; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05533411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533411.